EU funded Health research: Outcomes and perspectives in Horizon 2020

Ruxandra Draghia-Akli, MD, PhD
Director for Health Research
Directorate-General for Research and Innovation
European Commission
EU funded health research in figures (2002-2010)

- 1,210 projects funded
- 70,000 PubMed publications
- 4.9 billion euros invested
- 50,000 high-skilled jobs
- 14,000 teams
- 23.3% listed on patent application(s)
- 114 countries
- 17% envisage creating a SME
- ~50% of projects on-going
- 7.4% created one or more SMEs
EU vs. US: weaknesses of European health research

Low coordination, high fragmentation, invest less than in the US

Brain disease

Dementia

Cancer
Investment in R&D is part of the solution to exit from the economic crisis.

In Europe, private funding for R&D is particularly weak compared to the US.
Challenges

- Non-communicable diseases worldwide will cause an output loss of €35 trillion over the next two decades
- Increasing pressure on European healthcare systems
- The EU is not closing the persistent gap with global innovation leaders such as the US, Japan and South Korea
- Biomedical companies are finding drug development in Europe economically challenging and are moving their operations from the region, mainly to Asia
Horizon 2020: The next Framework Programme for research and innovation

Proposed budget: €80bn, a 46% increase compared to FP7

Europe needs cutting edge research and innovation
Essential to ensure competitiveness, growth and jobs
Vital to tackle pressing societal challenges
3% of GDP invested in R&D: headline target of Europe 2020
Horizon 2020: Health, Demographic Change and Wellbeing Challenge Proposal: ~ €8.5bn

Understanding the determinants of health (including environmental and climate related factors), improving health promotion and disease prevention;

Developing effective screening programmes and improving the assessment of disease susceptibility

Improving surveillance and preparedness

Understanding disease

Developing better preventive vaccines

Improving diagnosis

Using in-silico medicine for improving disease management and prediction

Treating disease

Transferring knowledge to clinical practice and scalable innovation actions

Better use of health data

Improving scientific tools and methods to support policy making and regulatory needs

Active ageing, independent and assisted living

Individual empowerment for self-management of health

Promoting integrated care

Optimising the efficiency and effectiveness of healthcare systems and reducing inequalities through evidence based decision making and dissemination of best practice, and innovative technologies and approaches.
Horizon 2020 novelties

Simplification:
- Simpler programme architecture, a single set of rules
- Easy to use cost reimbursement model: one project - one funding rate
- Less paperwork in preparing proposals
- Reduce time to grant by 100 days

Inclusive approach:
- More support for innovation and activities close to the market
- Strong focus on creating business opportunities
- New SBIR-like scheme dedicated to SMEs

Renewed successful partnerships:
- EDCTP
- IMI